
    
      The study will be a randomized open-label clinical trial conducted at a tertiary university
      hospital outpatient clinic and some private settings at Aswan governorate, Egypt, between
      January 2019 and March 2022. The authors will include women who asymptomatic pregnant women
      with a diagnosed placenta previa at 26-28 weeks gestation. They will be randomized into three
      groups: group I (vaginal progesterone suppositories ), group II (received an intramuscular
      dose of 250 mg 17-alpha-Hydroxyprogesterone caproate(17-OHPC) once a week) and group
      III(control group). In each group, Follow-up visits were performed every week then admission
      was done at 36 weeks at our university hospital. Scheduled caesarian section was done at
      completed 37 weeks unless otherwise required.
    
  